CUMBERLAND EMERGING TECHNOLOGIES ANNOUNCES NEW $2 MILLION SMALL BUSINESS GRANT AWARD

To support a novel lung cancer treatment

NASHVILLE, Tenn. (September 25, 2018) – Cumberland Emerging Technologies, Inc. (CET) today announced that the U.S. National Cancer Institute (NCI) has awarded $2 million in support of a joint research program involving *Cumberland Pharmaceuticals Inc., Cumberland Emerging Technologies, Inc.,* and researchers at *Vanderbilt University*. This Phase II grant is awarded under the Small Business Innovation Research (SBIR) funding mechanism and follows successful completion of an initial Phase I award.

The objective of the collaborative research program is to further develop a novel small molecule radiosensitizing agent for the treatment of certain lung cancers. By enhancing the cancer's sensitivity to radiation therapy, this technology addresses a significant medical need of improving clinical outcomes for these oncology patients.

Michael Freeman, Ph.D., Professor of Radiation Oncology at Vanderbilt University Medical Center is an Inventor of the technology and serves as a Principal Investigator of the NCI award. Cumberland will also enter into a research agreement with Vanderbilt University Medical Center to provide funding and support for the collaborative research program headed by Dr. Freeman, to achieve the objectives proposed in the grant submission.

In addition to project management and grant administration, CET is providing formulation, product development and regulatory support to help advance this technology and create a new drug product candidate for clinical use. CET's mission is to bring biomedical technologies and products conceived at southern research centers to the marketplace.

About Cumberland Emerging Technologies Inc.

Cumberland Emerging Technologies, Inc. ("CET") is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, Launch Tennessee, and China's Gloria Pharmaceuticals. CET is working with a select group of academic research institutions located in the mid-south region of the U.S to develop therapeutic compounds addressing poorly met medical needs. CET contributes product design and overall development support services to help university-based collaborators bridge the gap between discovery and the marketplace.

CET also operates the *Nashville Life Sciences Center* providing laboratory space, equipment, and infrastructure to support early-stage, life sciences companies.

For more information on CET see www.cet-fund.com